Opinion|Videos|February 10, 2025
The Economic Impact of Biosimilars
Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Biosimilars have been shown to reduce costs to the US health system overall. What kind of savings are you seeing in your health system since fully implementing biosimilars?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
3
FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6
4
Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD
5